NasdaqGM:CRSPBiotechs
Is It Time To Reassess CRISPR Therapeutics (CRSP) After Its 58% One-Year Surge?
If you are wondering whether CRISPR Therapeutics at around US$52 per share looks like an opportunity or a stock to be cautious on, the key is understanding what that price actually builds in.
The stock has delivered a 58.0% return over the last year, even though the year to date return is slightly negative at 2.6%, with shorter term moves of 0.6% over 7 days and 5.8% over 30 days adding extra noise on top.
Recent headlines around CRISPR Therapeutics have focused on its gene editing platform...